DK172110B1 - Fremgangsmåde til isolation af mutanter af DNA-sekvenser og anvendelsen heraf til identifikation af celleoverfladeproteiner - Google Patents
Fremgangsmåde til isolation af mutanter af DNA-sekvenser og anvendelsen heraf til identifikation af celleoverfladeproteiner Download PDFInfo
- Publication number
- DK172110B1 DK172110B1 DK172589A DK172589A DK172110B1 DK 172110 B1 DK172110 B1 DK 172110B1 DK 172589 A DK172589 A DK 172589A DK 172589 A DK172589 A DK 172589A DK 172110 B1 DK172110 B1 DK 172110B1
- Authority
- DK
- Denmark
- Prior art keywords
- cells
- antibody
- epitope
- antibodies
- cell surface
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 39
- 102000018697 Membrane Proteins Human genes 0.000 title claims abstract description 10
- 108010052285 Membrane Proteins Proteins 0.000 title claims abstract description 10
- 108091028043 Nucleic acid sequence Proteins 0.000 title claims description 13
- 230000027455 binding Effects 0.000 claims abstract description 72
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 28
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 21
- 210000004027 cell Anatomy 0.000 claims description 92
- 102100025237 T-cell surface antigen CD2 Human genes 0.000 claims description 45
- 101000934346 Homo sapiens T-cell surface antigen CD2 Proteins 0.000 claims description 44
- 108010041397 CD4 Antigens Proteins 0.000 claims description 32
- 239000013612 plasmid Substances 0.000 claims description 32
- 108020004414 DNA Proteins 0.000 claims description 24
- 239000000427 antigen Substances 0.000 claims description 19
- 108091007433 antigens Proteins 0.000 claims description 19
- 102000036639 antigens Human genes 0.000 claims description 19
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 14
- 230000000295 complement effect Effects 0.000 claims description 10
- 239000013598 vector Substances 0.000 claims description 9
- 241000588724 Escherichia coli Species 0.000 claims description 8
- 108060003951 Immunoglobulin Proteins 0.000 claims description 8
- 102000018358 immunoglobulin Human genes 0.000 claims description 8
- 239000000463 material Substances 0.000 claims description 8
- 241000283973 Oryctolagus cuniculus Species 0.000 claims description 6
- 101710160107 Outer membrane protein A Proteins 0.000 claims description 5
- 230000001464 adherent effect Effects 0.000 claims description 5
- 230000001580 bacterial effect Effects 0.000 claims description 4
- 239000000758 substrate Substances 0.000 claims description 4
- 230000002934 lysing effect Effects 0.000 claims description 3
- 241000282693 Cercopithecidae Species 0.000 claims description 2
- 241001494479 Pecora Species 0.000 claims description 2
- 230000009089 cytolysis Effects 0.000 claims description 2
- 210000004962 mammalian cell Anatomy 0.000 claims 11
- 238000003306 harvesting Methods 0.000 claims 2
- 210000003719 b-lymphocyte Anatomy 0.000 claims 1
- 230000001131 transforming effect Effects 0.000 claims 1
- 239000002299 complementary DNA Substances 0.000 abstract description 15
- 238000002955 isolation Methods 0.000 abstract description 15
- 239000003446 ligand Substances 0.000 abstract description 9
- 238000013507 mapping Methods 0.000 abstract description 6
- 238000004458 analytical method Methods 0.000 abstract description 4
- 238000013461 design Methods 0.000 abstract description 4
- 229940079593 drug Drugs 0.000 abstract description 4
- 239000003814 drug Substances 0.000 abstract description 4
- 230000000869 mutational effect Effects 0.000 abstract 1
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 69
- 230000035772 mutation Effects 0.000 description 53
- 238000006467 substitution reaction Methods 0.000 description 47
- 235000001014 amino acid Nutrition 0.000 description 40
- 241000725303 Human immunodeficiency virus Species 0.000 description 36
- 230000015572 biosynthetic process Effects 0.000 description 26
- 108091034117 Oligonucleotide Proteins 0.000 description 25
- 229940024606 amino acid Drugs 0.000 description 23
- 230000003993 interaction Effects 0.000 description 23
- 101100156338 Caenorhabditis elegans vit-4 gene Proteins 0.000 description 21
- 125000003275 alpha amino acid group Chemical group 0.000 description 20
- 150000001413 amino acids Chemical class 0.000 description 20
- 230000000694 effects Effects 0.000 description 19
- 108090000765 processed proteins & peptides Proteins 0.000 description 17
- 235000018102 proteins Nutrition 0.000 description 17
- 108010084313 CD58 Antigens Proteins 0.000 description 15
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 13
- 210000003743 erythrocyte Anatomy 0.000 description 13
- 102000004196 processed proteins & peptides Human genes 0.000 description 12
- 230000009257 reactivity Effects 0.000 description 10
- 230000017960 syncytium formation Effects 0.000 description 10
- 241000700605 Viruses Species 0.000 description 8
- 230000004913 activation Effects 0.000 description 6
- 238000010166 immunofluorescence Methods 0.000 description 6
- 102000053602 DNA Human genes 0.000 description 5
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 229920001184 polypeptide Polymers 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 108020004682 Single-Stranded DNA Proteins 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 238000003780 insertion Methods 0.000 description 4
- 230000037431 insertion Effects 0.000 description 4
- 230000036961 partial effect Effects 0.000 description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 4
- -1 radioisotopes Substances 0.000 description 4
- 230000010076 replication Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 241000288906 Primates Species 0.000 description 3
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 3
- 230000000890 antigenic effect Effects 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 238000004925 denaturation Methods 0.000 description 3
- 230000036425 denaturation Effects 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 230000004927 fusion Effects 0.000 description 3
- 238000010348 incorporation Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 102220231617 rs1064797198 Human genes 0.000 description 3
- 102200012887 rs121918638 Human genes 0.000 description 3
- 102220028365 rs386352375 Human genes 0.000 description 3
- 102220020965 rs80356883 Human genes 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- 208000030507 AIDS Diseases 0.000 description 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 2
- 102220526841 Basic salivary proline-rich protein 1_H26L_mutation Human genes 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 102000000844 Cell Surface Receptors Human genes 0.000 description 2
- 108010001857 Cell Surface Receptors Proteins 0.000 description 2
- 102220499111 Cytosol aminopeptidase_H26R_mutation Human genes 0.000 description 2
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 229920001917 Ficoll Polymers 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 2
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 2
- 102100034343 Integrase Human genes 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 108091060545 Nonsense suppressor Proteins 0.000 description 2
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 2
- 108091027568 Single-stranded nucleotide Proteins 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 230000006044 T cell activation Effects 0.000 description 2
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
- 241000700618 Vaccinia virus Species 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 230000003302 anti-idiotype Effects 0.000 description 2
- 235000009582 asparagine Nutrition 0.000 description 2
- 229960001230 asparagine Drugs 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 230000007910 cell fusion Effects 0.000 description 2
- 230000000120 cytopathologic effect Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000003278 mimic effect Effects 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 230000036438 mutation frequency Effects 0.000 description 2
- 102200084472 rs16976354 Human genes 0.000 description 2
- 102220094752 rs377388354 Human genes 0.000 description 2
- 102200017109 rs878855093 Human genes 0.000 description 2
- 102200138902 rs9606756 Human genes 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- 108010032595 Antibody Binding Sites Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 102100032768 Complement receptor type 2 Human genes 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 241000702224 Enterobacteria phage M13 Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241001288713 Escherichia coli MC1061 Species 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 101100005713 Homo sapiens CD4 gene Proteins 0.000 description 1
- 101000941929 Homo sapiens Complement receptor type 2 Proteins 0.000 description 1
- 101000884271 Homo sapiens Signal transducer CD24 Proteins 0.000 description 1
- 241000701024 Human betaherpesvirus 5 Species 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- 239000000232 Lipid Bilayer Substances 0.000 description 1
- 206010026749 Mania Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 230000004988 N-glycosylation Effects 0.000 description 1
- 108091007491 NSP3 Papain-like protease domains Proteins 0.000 description 1
- 108010021757 Polynucleotide 5'-Hydroxyl-Kinase Proteins 0.000 description 1
- 102000008422 Polynucleotide 5'-hydroxyl-kinase Human genes 0.000 description 1
- 102220636493 Ras-related protein Rab-27B_Q78L_mutation Human genes 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 108020005091 Replication Origin Proteins 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 230000006052 T cell proliferation Effects 0.000 description 1
- 108091008874 T cell receptors Proteins 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 102220536911 Transcription factor JunD_K46A_mutation Human genes 0.000 description 1
- 102220536966 Transcription factor JunD_K47A_mutation Human genes 0.000 description 1
- 102220546382 Vacuolar protein sorting-associated protein 41 homolog_K48A_mutation Human genes 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000037429 base substitution Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 102220346377 c.154T>G Human genes 0.000 description 1
- 102220149772 c.164A>G Human genes 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 210000004970 cd4 cell Anatomy 0.000 description 1
- 230000017455 cell-cell adhesion Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000011247 coating layer Substances 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 230000001461 cytolytic effect Effects 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 238000010612 desalination reaction Methods 0.000 description 1
- 239000005546 dideoxynucleotide Substances 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- 208000030172 endocrine system disease Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 125000001165 hydrophobic group Chemical group 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 210000004020 intracellular membrane Anatomy 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000007799 mixed lymphocyte reaction assay Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000007193 modulation by symbiont of host erythrocyte aggregation Effects 0.000 description 1
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 1
- 231100000150 mutagenicity / genotoxicity testing Toxicity 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 238000013492 plasmid preparation Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000009290 primary effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 230000012846 protein folding Effects 0.000 description 1
- 230000006916 protein interaction Effects 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 102200150038 rs104893702 Human genes 0.000 description 1
- 102220199342 rs1057521133 Human genes 0.000 description 1
- 102200149764 rs118204087 Human genes 0.000 description 1
- 102200155721 rs121918464 Human genes 0.000 description 1
- 102220188356 rs139135860 Human genes 0.000 description 1
- 102220256581 rs1553585708 Human genes 0.000 description 1
- 102220266317 rs1554949765 Human genes 0.000 description 1
- 102200091615 rs17887176 Human genes 0.000 description 1
- 102220015635 rs191057824 Human genes 0.000 description 1
- 102200120949 rs199517715 Human genes 0.000 description 1
- 102200158393 rs5030732 Human genes 0.000 description 1
- 102220037494 rs587780306 Human genes 0.000 description 1
- 102220225335 rs752355994 Human genes 0.000 description 1
- 102220198924 rs752781534 Human genes 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000036964 tight binding Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- 125000002264 triphosphate group Chemical class [H]OP(=O)(O[H])OP(=O)(O[H])OP(=O)(O[H])O* 0.000 description 1
- 125000000430 tryptophan group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C2=C([H])C([H])=C([H])C([H])=C12 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 229940035893 uracil Drugs 0.000 description 1
- 230000008478 viral entry into host cell Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1086—Preparation or screening of expression libraries, e.g. reporter assays
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70514—CD4
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
- G01N33/56972—White blood cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
- G01N33/56988—HIV or HTLV
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6878—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids in eptitope analysis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Biophysics (AREA)
- Pathology (AREA)
- Virology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Plant Pathology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Crystallography & Structural Chemistry (AREA)
- Bioinformatics & Computational Biology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- AIDS & HIV (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18182688A | 1988-04-15 | 1988-04-15 | |
US18182688 | 1988-04-15 |
Publications (3)
Publication Number | Publication Date |
---|---|
DK172589D0 DK172589D0 (da) | 1989-04-11 |
DK172589A DK172589A (da) | 1989-12-12 |
DK172110B1 true DK172110B1 (da) | 1997-10-27 |
Family
ID=22665974
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK172589A DK172110B1 (da) | 1988-04-15 | 1989-04-11 | Fremgangsmåde til isolation af mutanter af DNA-sekvenser og anvendelsen heraf til identifikation af celleoverfladeproteiner |
Country Status (8)
Country | Link |
---|---|
US (3) | US5411861A (de) |
EP (1) | EP0341444B1 (de) |
JP (1) | JPH02203787A (de) |
AT (1) | ATE114821T1 (de) |
DE (1) | DE68919524T2 (de) |
DK (1) | DK172110B1 (de) |
ES (1) | ES2065933T3 (de) |
PT (1) | PT90265B (de) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK172110B1 (da) | 1988-04-15 | 1997-10-27 | Gen Hospital Corp | Fremgangsmåde til isolation af mutanter af DNA-sekvenser og anvendelsen heraf til identifikation af celleoverfladeproteiner |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
CA2065010A1 (en) * | 1989-08-23 | 1991-02-24 | Brian Seed | Non-human primate cd4 polypeptides, fusions thereof, dna encoding, and uses thereof |
US7413537B2 (en) | 1989-09-01 | 2008-08-19 | Dyax Corp. | Directed evolution of disulfide-bonded micro-proteins |
JPH0725794B2 (ja) * | 1990-03-23 | 1995-03-22 | 呉羽化学工業株式会社 | 新規なペプチド |
CA2105300C (en) | 1991-03-01 | 2008-12-23 | Robert C. Ladner | Process for the development of binding mini-proteins |
GB9114734D0 (en) * | 1991-07-09 | 1991-08-28 | Univ London | Process for modifying proteins |
US5648220A (en) * | 1995-02-14 | 1997-07-15 | New England Medical Center Hospitals, Inc. | Methods for labeling intracytoplasmic molecules |
US6576465B1 (en) * | 1997-11-10 | 2003-06-10 | The Regents Of The University Of Michigan | Human bone accessory cells |
US6689566B1 (en) | 1999-01-14 | 2004-02-10 | Scantibodies Laboratory, Inc. | Methods, kits, and antibodies for detecting parathyroid hormone |
US7820393B2 (en) * | 1999-01-14 | 2010-10-26 | Scantibodies Laboratory, Inc. | Methods, kits and antibodies for detecting parathyroid hormone |
US20030186311A1 (en) * | 1999-05-21 | 2003-10-02 | Bioforce Nanosciences, Inc. | Parallel analysis of molecular interactions |
US20030228687A1 (en) * | 2000-08-07 | 2003-12-11 | The Regents Of The University Of Michigan | Human bone accessory cells |
DE10256042B4 (de) * | 2002-11-30 | 2006-06-08 | Universität Potsdam | Verfahren zur Selektion von Zellen, die spezifisch bindende Moleküle produzieren |
KR100540659B1 (ko) * | 2003-07-02 | 2006-01-10 | 삼성전자주식회사 | 이미지 확대 인쇄 방법과 장치 및 컴퓨터 프로그램을저장하는 컴퓨터로 읽을 수 있는 기록 매체 |
US20050202506A1 (en) * | 2004-03-11 | 2005-09-15 | Cantor Thomas L. | Methods for identifying and producing specific amino acid dependent antibodies and uses thereof |
WO2006025990A2 (en) * | 2004-07-27 | 2006-03-09 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Diseases Control And Prevention | Localization and characterization of flavivirus envelope glycoprotein cross-reactive epitopes and methods for their use |
AU2007200847B2 (en) * | 2004-07-27 | 2010-06-17 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES, CENTERS FOR DISEASE CONTROL AND PREVENTION | Localization and characterization of flavivirus envelope glycoprotein cross-reactive epitopes and methods for their use |
AU2017214692B2 (en) | 2016-02-06 | 2021-11-04 | Epimab Biotherapeutics, Inc. | Fabs-in-tandem immunoglobulin and uses thereof |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4361550A (en) * | 1979-12-04 | 1982-11-30 | Ortho Pharmaceutical Corporation | Complement-fixing monoclonal antibody to human suppressor T cells and methods of preparing same |
WO1983002058A1 (en) * | 1981-12-08 | 1983-06-23 | Univ South Carolina | Human monoclonal antibodies or lymphokines in separation of cells or diagnosis of mammary cancer |
US4677056A (en) * | 1983-08-18 | 1987-06-30 | Sloan-Kettering Institute For Cancer Research | Monoclonal antibody subsetting human helper and killer T-cells and method |
US4772552A (en) * | 1984-04-23 | 1988-09-20 | Dana-Farber Cancer Institute, Inc. | Monoclonal antibody which recognizes a 200-220 KD antigen on natural killer cells |
US4675285A (en) * | 1984-09-19 | 1987-06-23 | Genetics Institute, Inc. | Method for identification and isolation of DNA encoding a desired protein |
US4677061A (en) * | 1984-10-19 | 1987-06-30 | Genetic Systems Corporation | T-cell lymphocyte subset monitoring of immunologic disease |
US4818679A (en) * | 1985-02-19 | 1989-04-04 | The Trustees Of Columbia University In The City Of New York | Method for recovering mutant cells |
DK172110B1 (da) * | 1988-04-15 | 1997-10-27 | Gen Hospital Corp | Fremgangsmåde til isolation af mutanter af DNA-sekvenser og anvendelsen heraf til identifikation af celleoverfladeproteiner |
-
1989
- 1989-04-11 DK DK172589A patent/DK172110B1/da not_active IP Right Cessation
- 1989-04-13 ES ES89106627T patent/ES2065933T3/es not_active Expired - Lifetime
- 1989-04-13 DE DE68919524T patent/DE68919524T2/de not_active Expired - Fee Related
- 1989-04-13 PT PT90265A patent/PT90265B/pt active IP Right Grant
- 1989-04-13 AT AT89106627T patent/ATE114821T1/de not_active IP Right Cessation
- 1989-04-13 EP EP89106627A patent/EP0341444B1/de not_active Expired - Lifetime
- 1989-04-14 JP JP1096191A patent/JPH02203787A/ja active Pending
-
1992
- 1992-02-27 US US07/842,465 patent/US5411861A/en not_active Expired - Lifetime
-
1994
- 1994-10-11 US US08/320,663 patent/US5955264A/en not_active Expired - Fee Related
-
1999
- 1999-09-21 US US09/400,207 patent/US6579676B1/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
ATE114821T1 (de) | 1994-12-15 |
PT90265B (pt) | 1994-07-29 |
EP0341444B1 (de) | 1994-11-30 |
PT90265A (pt) | 1989-11-10 |
US5411861A (en) | 1995-05-02 |
DK172589D0 (da) | 1989-04-11 |
ES2065933T3 (es) | 1995-03-01 |
DK172589A (da) | 1989-12-12 |
US6579676B1 (en) | 2003-06-17 |
US5955264A (en) | 1999-09-21 |
DE68919524D1 (de) | 1995-01-12 |
DE68919524T2 (de) | 1995-05-04 |
EP0341444A2 (de) | 1989-11-15 |
EP0341444A3 (en) | 1990-11-14 |
JPH02203787A (ja) | 1990-08-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK172110B1 (da) | Fremgangsmåde til isolation af mutanter af DNA-sekvenser og anvendelsen heraf til identifikation af celleoverfladeproteiner | |
Peterson et al. | Genetic analysis of monoclonal antibody and HIV binding sites on the human lymphocyte antigen CD4 | |
Panté et al. | Interactions and three-dimensional localization of a group of nuclear pore complex proteins. | |
JPH02501192A (ja) | 可溶性t4蛋白を製造するためのdna配列、組換dna分子および方法 | |
Berger et al. | A soluble recombinant polypeptide comprising the amino-terminal half of the extracellular region of the CD4 molecule contains an active binding site for human immunodeficiency virus. | |
Berberian et al. | Immunoglobulin VH3 gene products: natural ligands for HIV gp120 | |
Low | Structure and function of the cytoplasmic domain of band 3: Center of erythrocyte membrane—Peripheral protein interactions | |
Sattentau et al. | The role of CD4 in HIV binding and entry | |
EP0510079B1 (de) | Durch menschliche lymphozyten produzierte proteine, die für diese proteine kodierende dns und pharmazeutische und biologische verwendungen | |
JPH06509462A (ja) | レセプターキメラ体による細胞性免疫の再設定 | |
JPH05505112A (ja) | Aids、arcおよびhiv感染の予防および治療に有用な抗cd4抗体ホモログ | |
JPH11505409A (ja) | 受容体キメラによる細胞性免疫の再指示 | |
JPH04507094A (ja) | ネコt細胞リンパトロピック レンチウィルスのポリペプチド | |
CN107001444A (zh) | 识别eb病毒短肽的t细胞受体 | |
JPH03504234A (ja) | 可溶性ヒトcd4断片及びその使用 | |
CN108503864A (zh) | 一种重组人β2-微球蛋白聚合物的制备方法 | |
Mutai et al. | PAL31, a novel nuclear protein, expressed in the developing brain | |
AU673810B2 (en) | Secreted Mac-2-binding glycoprotein | |
CN110144327A (zh) | 一种靶向性抗肿瘤t细胞及其制备方法和应用 | |
CN109251244A (zh) | 一种识别源自于ebv膜蛋白lmp1抗原的tcr | |
JPH08149981A (ja) | T細胞α鎖による抗原特異的免疫制御の方法 | |
CN109251243A (zh) | 一种识别sage1抗原的t细胞受体及编码该受体的核酸 | |
Quinkal et al. | Mapping of the interaction between the immunodominant loop of the ectodomain of HIV‐1 gp41 and human complement protein C1q | |
Mitchell et al. | Inactivation of a common epitope responsible for the induction of antibody-dependent enhancement of HIV | |
Willett et al. | cDNA cloning and eukaryotic expression of feline CD9 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B1 | Patent granted (law 1993) | ||
B1 | Patent granted (law 1993) | ||
PBP | Patent lapsed | ||
PBP | Patent lapsed |
Country of ref document: DK |